HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

N-methylnaloxone

quaternary derivative of naloxone
Also Known As:
N-methylnaloxone bromide; ORG 10908; ORG-10908; aloxone methylbromide; methyl naloxonium chloride; methylnaloxone; methylnaloxonium; methylnaloxonium bromide; methylnaloxonium bromide, (5alpha)-isomer; methylnaloxonium chloride; methylnaloxonium iodide; methylnaloxonium iodide, (5alpha)-isomer; methylnaloxonium sulfate (1:1), (5alpha)-isomer; methylnaloxonium, methyl sulfate, (5alpha)-isomer; naloxone MB; naloxone methiodide; naloxone methobromide; naloxone methoiodide; naloxone methyl bromide; naloxone methyl iodide
Networked: 65 relevant articles (4 outcomes, 6 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1. Maslov, Leonid N: 3 articles (09/2021 - 09/2013)
2. Blanpied, Catherine: 3 articles (07/2021 - 02/2018)
3. Cenac, Nicolas: 3 articles (07/2021 - 02/2018)
4. Dietrich, Gilles: 3 articles (07/2021 - 02/2018)
5. Basso, Lilian: 3 articles (01/2020 - 02/2018)
6. Oeltgen, Peter R: 2 articles (09/2021 - 01/2014)
7. Benamar, Mehdi: 2 articles (07/2021 - 01/2020)
8. Deraison, Céline: 2 articles (07/2021 - 01/2020)
9. Mas-Orea, Xavier: 2 articles (07/2021 - 01/2020)
10. Saoudi, Abdelhadi: 2 articles (07/2021 - 01/2020)

Related Diseases

1. Infarction (Infarctions)
10/29/2012 - "The prior introduction of naloxone methiodide abolished the cardioprotective effects of RIPC, RPOT but not IPC, as assessed by infarct size as a percentage of area at risk following 30min of ischaemia and 120min reperfusion. "
03/01/2021 - "Naltrexone and naloxone methiodide, the peripheral OR antagonists, and selective δ2-OR antagonist naltriben prevented the infarct size limiting effect of deltorphin II. Therefore, activation of peripheral δ2-OR enhanced cardiac resistance against toxic action of reperfusion. "
09/17/2013 - "The infarct size-limiting effect of CNH was abolished by OR antagonists naltrexone (non-selective), naloxone methiodide (non-selective peripherally acting), TIPP[ψ] (δ-OR), naltriben (δ2-OR), or CTAP (μ-OR), while BNTX (δ1-OR) and nor-binaltorphimine (κ-OR) had no effect. "
01/01/2021 - "Pretreatment with naltrexone, the peripherally acting opioid receptor antagonist naloxone methiodide, or the selective opioid kappa2 receptor antagonist nor-binaltorphimine completely abolished the infarct-reducing effect of (-)-U-50,488 and ICI 199,441. "
09/15/2021 - "The universal opioid receptor antagonists, naltrexone and naloxone methiodide acting on peripheral opioid receptor, as well as the selective opioid δ-receptor antagonist TIIP[ψ], the selective opioid δ2-receptor antagonist naltriben eliminated the infarct limiting effect of deltorphin II. The selective opioid κ receptor antagonist nor-binaltorphimine, the selective opioid μ receptor antagonist CTAP, and the selective opioid δ1-receptor antagonist BNTX did not abolish the protective effect of deltorphin II. Deltorphin II exhibited the most pronounced cardioprotective effect during reperfusion. "
2. Bradycardia
3. Substance Withdrawal Syndrome (Withdrawal Symptoms)
4. Pruritus (Itching)
5. Heart Failure

Related Drugs and Biologics

1. Opioid Analgesics (Opioids)
2. Morphine (MS Contin)
3. Narcotic Antagonists (Opioid Antagonists)
4. Opioid Receptors (Opioid Receptor)
5. mu Opioid Receptors (mu Opioid Receptor)
6. Naltrexone (ReVia)
7. norbinaltorphimine
8. naltrindole benzofuran
9. Ala(2)- deltorphin II
10. Pentobarbital (Nembutal)

Related Therapies and Procedures

1. Vagotomy
2. Intraperitoneal Injections
3. Analgesia
4. Injections
5. Ligation